SCHEMBL459615

SCHEMBL459615

NC1CCCC2CCC(O)CC12

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8010099 0.77 CA1 (0.33)
SCHEMBL9276620 0.76 MAPT (0.32) MEN1KMT2A
SCHEMBL18434998 0.76 MAPT (0.32) MEN1KMT2A
SCHEMBL21628145 0.76 MAPT (0.32) MEN1KMT2A
SCHEMBL30258679 0.75
SCHEMBL28249672 0.75 TSHR (0.36)
SCHEMBL24788125 0.73 THRB (0.44) THRBMEN1KMT2A
SCHEMBL10533313 0.73 THRB (0.44) THRBMEN1KMT2A
SCHEMBL22779289 0.71 CTDSP1 (0.32)
SCHEMBL11283293 0.71 MAPT (0.32) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110308790-A1 IN SITU METHANOGENESIS MODELING AND RISK ANALYSIS CONOCOPHILLIPS COMPANY (US) 2011-12-22 US claimed
WO-2011159919-A2 IN SITU METHANOGENESIS MODELING AND RISK ANALYSIS CONOCOPHILLIPS COMPANY (US) 2011-12-22 WO claimed
US-10358660-B2 Compositions and methods for identifying and modifying carbonaceous compositions TAXON BIOSCIENCES, INC. (US) 2019-07-23 US disclosed
US-10221432-B2 In situ methanogenesis modeling and risk analysis CONOCOPHILLIPS COMPANY (US) 2019-03-05 US disclosed
EP-2582846-B1 COMPOSITIONS AND METHODS FOR IDENTIFYING AND MODIFYING CARBONACEOUS COMPOSITIONS TAXON BIOSCIENCES INC (US) 2018-11-28 EP disclosed
US-20180223316-A1 COMPOSITIONS AND METHODS FOR IDENTIFYING AND MODIFYING CARBONACEOUS COMPOSITIONS TAXON BIOSCIENCES INC. (US) 2018-08-09 US disclosed
US-20180163234-A1 COMPOSITIONS AND METHODS FOR IDENTIFYING AND MODIFYING CARBONACEOUS COMPOSITIONS TAXON BIOSCIENCES, INC. (US) 2018-06-14 US disclosed
US-20160108435-A1 COMPOSITIONS AND METHODS FOR IDENTIFYING AND MODIFYING CARBONACEOUS COMPOSITIONS TAXON BIOSCIENCES INC (US) 2016-04-21 US disclosed
US-9206680-B2 Compositions and methods for identifying and modifying carbonaceous compositions TAXON BIOSCIENCES INC (US) 2015-12-08 US disclosed
US-20130116126-A1 COMPOSITIONS AND METHODS FOR IDENTIFYING AND MODIFYING CARBONACEOUS COMPOSITIONS TAXON BIOSCIENCES, INC. (US) 2013-05-09 US disclosed
EP-2582846-A2 COMPOSITIONS AND METHODS FOR IDENTIFYING AND MODIFYING CARBONACEOUS COMPOSITIONS Taxon Biosciences, Inc. (US) 2013-04-24 EP disclosed
EP-1885704-B1 ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF ABBOTT LAB (US) 2011-09-28 EP disclosed
US-20110144057-A1 ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF ABBOTT LABORATORIES (US) 2011-06-16 US disclosed
US-7902236-B2 Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof ABBOTT LABORATORIES (US) 2011-03-08 US disclosed
US-20100010055-A1 ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF ABBOTT LABORATORIES (US) 2010-01-14 US disclosed
US-7504520-B2 Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
CN-101248052-A Vanilloid receptor subtype 1(VR1) antagonists and uses thereof ABBOTT LAB (US) 2008-08-20 CN disclosed
EP-1885704-A2 ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF Abbott Laboratories (US) 2008-02-13 EP disclosed
US-20060281799-A1 Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof ABBVIE INC. 2006-12-14 US disclosed
WO-2006122250-A2 ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF ABBOTT LABORATORIES (US) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281799-A1 Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof TRPV1, TMEM109, CACNA1E THRB 1193/4885MEN1 3283/4885KMT2A 3658/4885
US-20110144057-A1 ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF TRPV1, TMEM109, CACNA1E THRB 1193/4885MEN1 3283/4885KMT2A 3658/4885
US-20100010055-A1 ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF TRPV1, TMEM109, CACNA1E THRB 1193/4885MEN1 3283/4885KMT2A 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.